Shortening HCV therapy: science meets public health

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 11, 2017, Pages 771-772

  Lau, George ^a,b  

^a Beijing 302 Hong Kong Humanity and Health Hepatitis C Diagnosis and Treatment Centre   (China)

^b Humanity and Health Clinic   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; PROTEINASE INHIBITOR; RUZASVIR; UPRIFOSBUVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DIRECT ACTING ANTIVIRAL AGENTS; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HUMAN; LOW INCOME COUNTRY; NOTE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS INFECTION; PUBLIC HEALTH;

HEPATITIS C, CHRONIC; HUMANS; PUBLIC HEALTH;

EID: 85032257014     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30215-7     Document Type: Note

References (9)

1. WHO. Global hepatitis report 2017, 2017, World Health Organization, Geneva.
2. Wilson, EM, Kattakuzhy, S, Sidharthan, S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis 62 (2016), 280–288.
3. Koizumi, Y, Ohashi, H, Nakajima, S, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA 114 (2017), 1922–1927.
4. Lau, G, Benhamou, Y, Chen, G, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 1 (2016), 97–104.
5. Gane, EJ, Pianko, S, Roberts, SK, et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in patients without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30159-0.
6. Lawitz, E, Buti, M, Vierling, JM, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in patients with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30163-2.
7. Kohli, A, Osinusi, A, Sims, Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385 (2015), 1107–1113.
8. Emmanuel, B, Wilson, EM, O'Brien, TR, Kottilil, S, Lau, G, Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30053-5.
9. Perelson, AS, Guedj, J, Modelling hepatitis C therapy-predicting effects of treatment. Nat Rev Gastroenterol Hepatol 12 (2015), 437–445.